Skip to main content

SPONSORED EPISODE: Europe’s ambition to stop cancer

POLITICO
16 lis 2026, 15:01Business
Oryginał
1 min read

Europe leads in cancer research but struggles to translate innovations into patient treatments, with the disease costing the economy over €200 billion annually.

Every minute, five people in Europe are diagnosed with cancer, imposing a heavy economic burden of more than €200 billion annually. Despite Europe's leadership in cancer research, the European Court of Auditors and European Parliament have found that the Beating Cancer Plan, launched five years ago, is falling short in implementation.

Implementation challenges

National cancer plans often lack sufficient resources to succeed, while access to care varies widely across member countries. Compounding the issue, Europe's share of global commercial clinical trials has almost halved in the past decade, indicating a growing gap between research and practical application.

Europe has a chance to close the gap between innovation and access.

POLITICO Studio

Policy opportunities

With the EU's proposed Biotech Act under negotiation and discussions on the bloc's next long-term budget underway, experts are calling for stronger policies to ensure every patient benefits from cancer care innovations. Elisabetta Zanon, CEO of the European Cancer Organisation, emphasizes the need for patient voices in policymaking, while Jennifer Young of Pfizer highlights the importance of speeding up clinical trials.

Z.ai
Article written by AI
Z.ai GLM-4.5-FlashFree
Free AI articles150 of 150
No limit after signing in with Telegram